Sublimity Therapeutics

Please note: The information displayed on this page might be outdated.
Sublimity Therapeutics: Provider of an oral drug delivery technology intended to offer therapies for gastrointestinal and immunological diseases and disorders. The company's proprietary SmPill platform technology allows for oral delivery of difficult-to-formulate drugs, addressing issues of solubility and permeability to make drugs bioavailable and also targeting drugs for delivery systemically or locally to parts of the GI tract, providing clients with oral drug formulation of both small and large molecules, and potentially biologics including antibodies and other proteins.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Disease Space
Autoimmune
Listing
Private
Website:
Address:
DCU Alpha Innovation Campus
Old Finglas Road
Dublin, Dublin D11 KXN4
Ireland

Company Participants at 2nd Solebury Trout Virtual Global Healthcare Conference Series

Albert Agro
Sublimity Therapeutics, President & CEO
Dr. Agro is an internationally recognized clinical development expert with more than 25 years of experience in IBD, Diabetes, and CNS New Drug Applications and approvals. Most recently, Albert was the Chief Medical Officer for Cynapsus Therapeutics, a specialty pharma CNS company that developed the first successful sublingual apomorphine thin strip for Parkinson’s disease. At Cynapsus, he was instrumental in initializing the company’s IPO, NASDAQ listing, and US$640 million acquisition by Sunovion Pharmaceuticals. Albert is also the Co-Founder of GRi Bio, a clinical-stage company in NASH. He has held executive positions at Versanum (CEO), Cynapsus (CMO), Ironshore Pharma (CMO), Trillium Therapeutics Inc. (CMO), Stem Cell Therapeutics (CMO) and TransTech Pharma (EVP), and has facilitated the successful licensing of major assets to Pfizer ($3 Billion), Forest Labs ($1.05 billion), Novo Nordisk and Merck. He serves as Director at Saint Elizabeth Health Care and has maintained a position as Professor, Department of Pathology and Molecular Medicine at McMaster University in Hamilton, Ontario since September 1996. He is the recipient of a Michael J. Fox Foundation Clinical Scholarship for his work on Apomorphine. He is an Undergraduate of Iowa State University, University of Guelph. Albert holds a Ph.D. from Department of Medicine at McMaster University in 1995 and a post-doctoral fellowship from University of Florence in Italy.